Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Galantamine in Vascular Dementia (GAL-INT-26)
NCT00035191Phase 3Completed
- Sponsor
- Johnson & Johnson
- Start
- Oct 2001
- Modality
- Nucleic Acid-Directed Small Molecules, Classical Binding Small Molecules, Metabolically Activated Prodrugs
01
Overview
A Phase 3 trial of galantamine in vascular dementia, sponsored by Johnson & Johnson. Started Oct 2001; status: completed.
02
Drugs
galantamine
03
Conditions
vascular dementia
Beyond the preview
Go deeper on NCT00035191.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00035191.